Compare LOCL & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCL | IFRX |
|---|---|---|
| Founded | 2021 | 2007 |
| Country | United States | Germany |
| Employees | 333 | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6M | 60.6M |
| IPO Year | N/A | 2017 |
| Metric | LOCL | IFRX |
|---|---|---|
| Price | $1.13 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 23.0K | ★ 171.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.93 | N/A |
| Revenue Next Year | $82.62 | $1,054.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.98 | $0.71 |
| 52 Week High | $5.75 | $1.94 |
| Indicator | LOCL | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 29.32 | 52.69 |
| Support Level | $0.98 | $0.75 |
| Resistance Level | $2.75 | $1.16 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 22.18 | 50.85 |
Local Bounti Corp is a controlled environment agriculture company. Its business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides, it delivers products that have a longer shelf life, and are good in taste.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.